Protocol Ledger

NCT07222761 · Phase III · RECRUITING

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Interventional Phase III clinical trial protocol NCT07222761 sponsored by Regeneron Pharmaceuticals in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-02 Enrollment: 915 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07222761
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)915 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07222761
Protocol FieldVerified Registry Value
NCT IdentifierNCT07222761
Consolidated Lead SponsorRegeneron Pharmaceuticals
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment915 participants (ESTIMATED)
Registered Start Date2026-01-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07222761
Hospital Research SiteLocationSite Profile
Emory Winship Cancer InstituteAtlanta, GAOpen Hospital Dossier ->
Memorial Sloan Kettering Cancer CenterNew York, NYOpen Hospital Dossier ->
Baylor University Medical CenterDallas, TXOpen Hospital Dossier ->
Austin HospitalHeidelberg, AustraliaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Regeneron Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI